Regulus Therapeutics said this week that it has identified a third, undisclosed microRNA target under its ongoing collaboration with GlaxoSmithKline.
The discovery triggers a preclinical milestone payment of an undisclosed amount, Regulus said.
The companies began working together in 2008, and expanded their alliance in 2010 (GSN 2/25/2010).